Study of oral NA-921 vs placebo for girls and women with Rett syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests an oral medication called NA-921 in females with Rett syndrome to see if it works better than a placebo. It may be an option for those who have a confirmed MECP2 gene mutation and stable seizure patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 5 and 20 years old.
- You weigh at least 12 kilograms (about 26.5 pounds).
- You can swallow a liquid medicine or get it through a feeding tube.
- You have been diagnosed with classic Rett syndrome and have a MECP2 mutation.
- Your seizures have been stable or you've had none in the past 8 weeks.
- You are not pregnant, breastfeeding, and if applicable, agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called NTI164 to see if it can safely help manage Rett syndrome symptoms in girls and young women. It is for those with classic Rett syndrome who have been stable recently and are not using certain other treatments.
This trial tests whether vorinostat is safe and helpful for girls and young women with Rett syndrome. Participants must have a confirmed MeCP2 mutation and be in a stable phase of the condition.
This Phase 2 trial studies whether an antioxidant “cocktail” helps children and teens with Rett syndrome compared with a placebo (inactive drink). If you join, you’ll get study assessments and blood tests to see if the treatment is safe and helpful.
This study tests whether fenfluramine, a medication already used for seizures, can help people with Rett syndrome. It aims to see if it improves daily life and reduces symptoms.
This trial tests a gene-editing approach for Rett syndrome in children who have a confirmed MECP2 gene mutation. It may help by targeting specific “hotspot” genetic changes that cause the condition.
This study measures brain and nerve activity (brain signals) to find patterns that match Rett syndrome. It may help researchers better track Rett changes over time and develop more precise ways to measure response in future treatments.
Hear when a new Rett Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.